X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Panacea Biotech with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs MYLAN (US) - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PANACEA BIOTECH   MYLAN
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
MYLAN
Dec-14
PANACEA BIOTECH/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1493,805-   
Low Rs822,682-   
Sales per share (Unadj.) Rs84.11,302.8-  
Earnings per share (Unadj.) Rs-18.3156.9-  
Cash flow per share (Unadj.) Rs-6.7252.6-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs83.7647.6-  
Shares outstanding (eoy) m61.25378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x1.42.5 55.1%   
Avg P/E ratio x-6.320.7 -30.5%  
P/CF ratio (eoy) x-17.212.8 -134.3%  
Price / Book Value ratio x1.45.0 27.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,0741,227,273 0.6%   
No. of employees `0002.825.0 11.0%   
Total wages/salary Rs m1,4490-   
Avg. sales/employee Rs Th1,874.119,716.9 9.5%   
Avg. wages/employee Rs Th527.00-   
Avg. net profit/employee Rs Th-407.72,375.2 -17.2%   
INCOME DATA
Net Sales Rs m5,154492,922 1.0%  
Other income Rs m100-2,873 -3.5%   
Total revenues Rs m5,254490,049 1.1%   
Gross profit Rs m-766122,592 -0.6%  
Depreciation Rs m71136,203 2.0%   
Interest Rs m1,50321,262 7.1%   
Profit before tax Rs m-2,88162,254 -4.6%   
Minority Interest Rs m11-255 -4.2%   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m172,618 0.6%   
Profit after tax Rs m-1,12159,381 -1.9%  
Gross profit margin %-14.924.9 -59.8%  
Effective tax rate %-0.64.2 -13.9%   
Net profit margin %-21.812.0 -180.6%  
BALANCE SHEET DATA
Current assets Rs m3,810433,344 0.9%   
Current liabilities Rs m8,365338,788 2.5%   
Net working cap to sales %-88.419.2 -460.8%  
Current ratio x0.51.3 35.6%  
Inventory Days Days15678 199.4%  
Debtors Days Days67107 62.7%  
Net fixed assets Rs m14,480114,036 12.7%   
Share capital Rs m6117,431 0.4%   
"Free" reserves Rs m9030-   
Net worth Rs m5,127245,031 2.1%   
Long term debt Rs m5,832366,052 1.6%   
Total assets Rs m19,433986,961 2.0%  
Interest coverage x-0.93.9 -23.3%   
Debt to equity ratio x1.11.5 76.1%  
Sales to assets ratio x0.30.5 53.1%   
Return on assets %2.08.2 24.0%  
Return on equity %-21.924.2 -90.2%  
Return on capital %3.613.6 26.7%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Net fx Rs m5970-   
CASH FLOW
From Operations Rs m59964,795 0.9%  
From Investments Rs m-438-51,099 0.9%  
From Financial Activity Rs m-303-17,073 1.8%  
Net Cashflow Rs m-141-3,378 4.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 63.85 Rs / USD

Compare PANACEA BIOTECH With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare PANACEA BIOTECH With: AUROBINDO PHARMA  WOCKHARDT LTD.  SHASUN PHARMA  DR. DATSONS LABS  DIVIS LABORATORIES  



Today's Market

Of Rising Stock Markets, Reduction in Government's Additional Borrowing, and Top Cues in Focus Today(Pre-Open)

Share markets in India closed on a strong note yesterday. At the closing bell yesterday, the BSE Sensex crossed its 35,000 mark for the first time and stood higher by 311 points (up 0.9%).

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Jan 17, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS